EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Acromegaly is associated with an increased incidence of primary malignant tumors: data from a national study in Sweden

Erika Tsatsaris iD, Jonas Robèrt iD, Pia Burman iD, Katarina Berinder iD, Lorenza Bonelli iD, Per Dahlqvist iD, Charlotte Höybye iD, Oskar Ragnarsson iD, Konstantina Vouzouneraki iD, Anna-Karin Åkerman iD, Bertil Ekman iD, Britt Edén Engström iD

The Journal of Clinical Endocrinology & Metabolism · 2026

DOI: 10.1210/clinem/dgag137 ↗

Kurz gefasst

Fachartikel in der Zeitschrift The Journal of Clinical Endocrinology & Metabolism, 2026. Verfasst von Erika Tsatsaris und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Sciences, Endocrinology and Mineral Metabolism, Uppsala University Hospital, Uppsala University, Uppsala SE-751 85, Sweden. Hauptthemen laut MEDLINE: Acromegaly, Neoplasms. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 49 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Swedish government, county council of Uppsala, Medical Research Council of Southeast Sweden.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Context

GH excess and elevated IGF-1 in acromegaly are considered to promote cancer development.

Objective

To investigate cancer incidence and outcome in patients with acromegaly in relation to biochemical control.

Methods

Matched cohort study in patients with acromegaly diagnosed from 1991 to 2018 and 10 controls per case from the Swedish population. Cancer diagnoses and fatalities were obtained from the Swedish Pituitary and National Patient Registers. Adjusted hazard ratio (HR) and 95% confidence intervals (CIs) for cancer incidence and death were estimated using a Cox proportional hazard regression model adjusted for age, sex, and comorbidity.

Results

We included 1035 patients with acromegaly (49.5% female; median age 52.0 years) and 10 261 matched controls. Patients had higher adjusted HR (95% CI) for all cancer (1.28, 1.11-1.49), colorectal cancer (1.84, 1.28-2.64), lung cancer (1.95, 1.22-3.11), hematologic cancer (1.68, 1.03-2.73), and breast cancer in women (1.46, 1.02-2.11) from 5 years before acromegaly diagnosis. Second cancers after diagnosis tended to be increased (1.54, 0.98-2.44). Death from cancer was only significantly elevated in patients 40 to 60 years of age (1.48, 1.19-1.85). Patients with persistently elevated IGF-1 had a higher overall mortality rate (1.50, 1.10-2.01) but no increase in cancer incidence or cancer-related mortality compared to biochemically controlled patients.

Conclusion

This nationwide, matched cohort study showed an increased risk of cancer in patients with acromegaly, underscoring the importance of vigilance for early signs of cancer after acromegaly diagnosis. Biochemical control had minor effects on increased cancer development, indicating an effect beyond GH hypersecretion.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

AcromegalyNeoplasmsHumansFemaleSwedenMiddle AgedMaleIncidenceAdultRegistriesAgedCase-Control StudiesCohort StudiesInsulin-Like Growth Factor IFollow-Up StudiesRisk Factors

Stichwörter der Autor:innen

acromegalycancermortalitypatient register

Substanzen

Insulin-Like Growth Factor I

Autor:innen und Institutionen

  • Department of Medical Sciences, Endocrinology and Mineral Metabolism, Uppsala University Hospital, Uppsala University, Uppsala SE-751 85, Sweden.
  • Departments of Endocrinology in Linköping and Norrköping, and Department of Health, Medicine and Caring Sciences, Linköping University, Linköping SE-581 83, Sweden.
  • Department of Endocrinology, Skåne University Hospital Malmö, Lund University, Malmö SE-205 02, Sweden.
  • Department of Endocrinology, Karolinska University Hospital, Stockholm SE-171 76, Sweden.
  • Department of Molecular Medicine and Surgery, Karolinska Institutet, Stockholm SE-171 76, Sweden.
  • Department of Public Health and Clinical Medicine, Umeå University, Umeå SE-901 87, Sweden.

ORCID-Profile: Erika Tsatsaris, Jonas Robèrt, Pia Burman, Katarina Berinder, Lorenza Bonelli, Per Dahlqvist, Charlotte Höybye, Oskar Ragnarsson, Konstantina Vouzouneraki, Anna-Karin Åkerman, Bertil Ekman, Britt Edén Engström

Förderung

  • Swedish government
  • county council of Uppsala
  • Medical Research Council of Southeast Sweden
  • Pfizer, Inc

Zitieren

APA

Tsatsaris, E., Robèrt, J., Burman, P., Berinder, K., Bonelli, L., Dahlqvist, P., Höybye, C., Ragnarsson, O., Vouzouneraki, K., Åkerman, A. K., Ekman, B., & Engström, B. E. (2026). Acromegaly is associated with an increased incidence of primary malignant tumors: data from a national study in Sweden. The Journal of Clinical Endocrinology & Metabolism. https://doi.org/10.1210/clinem/dgag137

Vancouver

Tsatsaris E, Robèrt J, Burman P, Berinder K, Bonelli L, Dahlqvist P, et al. Acromegaly is associated with an increased incidence of primary malignant tumors: data from a national study in Sweden. The Journal of Clinical Endocrinology & Metabolism. 2026. doi:10.1210/clinem/dgag137

BibTeX
@article{Tsatsaris2026,
  author = {Tsatsaris, Erika and Robèrt, Jonas and Burman, Pia and Berinder, Katarina and Bonelli, Lorenza and Dahlqvist, Per and Höybye, Charlotte and Ragnarsson, Oskar and Vouzouneraki, Konstantina and Åkerman, Anna-Karin and Ekman, Bertil and Engström, Britt Edén},
  title = {Acromegaly is associated with an increased incidence of primary malignant tumors: data from a national study in Sweden},
  journal = {The Journal of Clinical Endocrinology & Metabolism},
  year = {2026},
  doi = {10.1210/clinem/dgag137}
}
Kostenlos starten →